share_log

Cantor Fitzgerald Reiterates Neutral on Intra-Cellular Therapies, Maintains $132 Price Target

Benzinga ·  Apr 2 14:32

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and maintains $132 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 318

Recommended

Write a comment